The Cystic Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Cystic Fibrosis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cystic Fibrosis Market.
Some of the key takeaways from the Cystic Fibrosis Pipeline Report:
Companies across the globe are diligently working toward developing novel Cystic Fibrosis treatment therapies with a considerable amount of success over the years.
Cystic Fibrosis companies working in the treatment market are Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex Pharmaceuticals, AbbVie, Armata Pharmaceuticals, 4D Molecular Therapeutics, Eloxx Pharmaceuticals, Verona Pharma, University of North Carolina, Aridis Pharmaceuticals, 4D Molecular Therapeutics, Boehringer Ingelheim, Hartford Hospital, Clarametyx Biosciences, Inc., Insmed Incorporated, Haisco Pharmaceutical, BiomX, Inc., Respirion Pharmaceuticals, and others, are developing therapies for the Cystic Fibrosis treatment
Emerging Cystic Fibrosis therapies in the different phases of clinical trials are- SP-101, LUNAR CF, KB407, Galicaftor/Navoc aftor/ABBV-576, AP-PA02, 4D-710, ELX-02, Ensifentrine, Deutivacaftor/tez acaftor/vanzacaft, Mannitol Inhalant Product, VX-522 mRNA therapy, Inhaled AR-501, 4D-710, BI 1291583, Cefiderocol, CMTX-101, Brensocatib, HSK31858, BX004-A, RSP-1502, and others are expected to have a significant impact on the Cystic Fibrosis market in the coming years.
In March 2024, Sionna Therapeutics has secured $182 million in a Series C financing round to further develop additional cystic fibrosis treatments for clinical trials. This round, which was increased and oversubscribed, will enable Sionna to continue advancing its clinical development of therapies aimed at stabilizing the first nucleotide-binding domain (NBD1) in cystic fibrosis patients.
In August 2023, Porosome Therapeutics has announced a potentially innovative treatment for cystic fibrosis, revealing that it has filed a comprehensive patent for this new therapy targeting cystic fibrosis and other diseases. The biopharma describes this treatment as the first application of the porosome, the secretory portal in cells. Porosomes are lipoproteins located at the cell plasma membrane that facilitate cellular communication by secreting chemical messages essential for sustaining life. Defects in porosome secretion are linked to diseases such as neurological disorders, immune disorders, various cancers, diabetes, and cystic fibrosis.
Cystic Fibrosis Overview
Cystic fibrosis (CF) is a genetic disorder that primarily affects the respiratory and digestive systems. It is caused by mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene, which encodes a protein responsible for regulating the movement of salt and water in and out of cells.
Get a Free Sample PDF Report to know more about Cystic Fibrosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/cystic-fibrosis-pipeline-insight
Emerging Cystic Fibrosis Drugs Under Different Phases of Clinical Development Include:
SP-101: Spirovant Sciences
LUNAR CF: Arcturus Therapeutics
KB407: Krystal Biotech
Galicaftor/Navoc aftor/ABBV-576: AbbVie
AP-PA02: Armata Pharmaceuticals
4D-710: 4D Molecular Therapeutics
ELX-02: Eloxx Pharmaceuticals
Ensifentrine: Verona Pharma
Deutivacaftor/tez acaftor/vanzacaft: Vertex Pharmaceuticals
Mannitol Inhalant Product: University of North Carolina
VX-522 mRNA therapy: Vertex Pharmaceuticals
Inhaled AR-501: Aridis Pharmaceuticals
BI 1291583: Boehringer Ingelheim
Cefiderocol: Hartford Hospital
CMTX-101: Clarametyx Biosciences, Inc.
Brensocatib: Insmed Incorporated
HSK31858: Haisco Pharmaceutical
BX004-A: BiomX, Inc.
RSP-1502: Respirion Pharmaceuticals
Cystic Fibrosis Route of Administration
Cystic Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Cystic Fibrosis Molecule Type
Cystic Fibrosis Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Cystic Fibrosis Pipeline Therapeutics Assessment
Cystic Fibrosis Assessment by Product Type
Cystic Fibrosis By Stage and Product Type
Cystic Fibrosis Assessment by Route of Administration
Cystic Fibrosis By Stage and Route of Administration
Cystic Fibrosis Assessment by Molecule Type
Cystic Fibrosis by Stage and Molecule Type
DelveInsight’s Cystic Fibrosis Report covers around 80+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Cystic Fibrosis product details are provided in the report. Download the Cystic Fibrosis pipeline report to learn more about the emerging Cystic Fibrosis therapies
Some of the key companies in the Cystic Fibrosis Therapeutics Market include:
Key companies developing therapies for Cystic Fibrosis are – F. Hoffmann-La Roche Ltd, Gilead Sciences Inc., Mylan NV, AbbVie Inc., Alaxia, Allergan, AstraZeneca, Beyond Air Inc., Teva Pharmaceutical Industries Ltd, Vertex Pharmaceuticals Incorporated, and others.
Cystic Fibrosis Pipeline Analysis:
The Cystic Fibrosis pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Cystic Fibrosis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cystic Fibrosis Treatment.
Cystic Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Cystic Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cystic Fibrosis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Cystic Fibrosis drugs and therapies
Cystic Fibrosis Pipeline Market Drivers
Rising incidence of Cystic Fibrosis, advance research and development over the last few years have contributed to get a clearer picture of the disease, development of the healthcare industry are some of the important factors that are fueling the Cystic Fibrosis Market.
Cystic Fibrosis Pipeline Market Barriers
However, No standard cure for cystic fibrosis, adverse effects associated with the drugs and other factors are creating obstacles in the Cystic Fibrosis Market growth.
Scope of Cystic Fibrosis Pipeline Drug Insight
Coverage: Global
Key Cystic Fibrosis Companies: Spirovant Sciences, Arcturus Therapeutics, Krystal Biotech, Vertex Pharmaceuticals, AbbVie, Armata Pharmaceuticals, 4D Molecular Therapeutics, Eloxx Pharmaceuticals, Verona Pharma, University of North Carolina, Aridis Pharmaceuticals, 4D Molecular Therapeutics, Boehringer Ingelheim, Hartford Hospital, Clarametyx Biosciences, Inc., Insmed Incorporated, Haisco Pharmaceutical, BiomX, Inc., Respirion Pharmaceuticals, and others
Key Cystic Fibrosis Therapies: SP-101, LUNAR CF, KB407, Galicaftor/Navoc aftor/ABBV-576, AP-PA02, 4D-710, ELX-02, Ensifentrine, Deutivacaftor/tez acaftor/vanzacaft, Mannitol Inhalant Product, VX-522 mRNA therapy, Inhaled AR-501, 4D-710, BI 1291583, Cefiderocol, CMTX-101, Brensocatib, HSK31858, BX004-A, RSP-1502, and others
Cystic Fibrosis Therapeutic Assessment: Cystic Fibrosis current marketed and Cystic Fibrosis emerging therapies
Cystic Fibrosis Market Dynamics: Cystic Fibrosis market drivers and Cystic Fibrosis market barriers
Request for Sample PDF Report for Cystic Fibrosis Pipeline Assessment and clinical trials
Table of Contents
1. Cystic Fibrosis Report Introduction
2. Cystic Fibrosis Executive Summary
3. Cystic Fibrosis Overview
4. Cystic Fibrosis- Analytical Perspective In-depth Commercial Assessment
5. Cystic Fibrosis Pipeline Therapeutics
6. Cystic Fibrosis Late Stage Products (Phase II/III)
7. Cystic Fibrosis Mid Stage Products (Phase II)
8. Cystic Fibrosis Early Stage Products (Phase I)
9. Cystic Fibrosis Preclinical Stage Products
10. Cystic Fibrosis Therapeutics Assessment
11. Cystic Fibrosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Cystic Fibrosis Key Companies
14. Cystic Fibrosis Key Products
15. Cystic Fibrosis Unmet Needs
16 . Cystic Fibrosis Market Drivers and Barriers
17. Cystic Fibrosis Future Perspectives and Conclusion
18. Cystic Fibrosis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/
